Audrey’s Life Science Meeting Picks for February - March 2011 Complimentary Service of AudreysNetwork.com

(Feb. 7, 2011 Edition) **************************************************************** SBODN Live and Virtual, Monday Evening, Feb. 7, 2011 Topic: “So You Think You Want an Employee Curriculum: Stakeholder Engagement in a Biotech Company” Speakers/Presenters - Jay Orlin and Ron Sacchi Date and Time: Monday, Feb. 7, 2011 5:30pm - Networking 6- 7pm – Talk Location: Citrix, 4988 Great America Pkwy, Santa Clara Online at GoToWebinar - 6- 7 pm Register: $20 Advance, $25 Door, $10 Students/Job Seekers. Topic Description As heads of training, Jay Orlin and Ron Sacchi have been responsible for delivering curricula and courseware for many thousands of people during their careers. In this session they will focus on employee development curricula and share lessons learned about how to approach the challenges of building and sustaining organizational support, setting and modifying expectations, designing curricula, and piloting programs. As one of them said " sometimes you learn more from the things that didn't work than you do from smooth successes." Speaker Bios Jay Orlin is a Learning and Development expert. He has extensive management experience leading L&D departments and programs at Intel, Nortel, Tandem, Altera and Philips Medical. In addition to his in- house experience, Jay has executed over a hundred performance improvement projects for large and small companies, such as; Hewlett Packard, Sun Microsystems, Oracle, Pacific Bell, Charles Schwab, ProBusiness, Aspect Telecommunications, Avery Dennison, Bayer Pharmaceuticals, Cisco Systems, Raychem and Gilead Life Sciences. Ron Sacchi brings decades of leadership and management experience to the organizational development arena. Because of his business acumen and creative approaches to change, he is respected in the HR community specifically for the ability to direct, motivate, influence and inspire leaders to improve performance.Some of his most recent clients include: eBay, Cisco, Maxim, Cognizant, LiveOps, 511.Org, SunPower, Intel and Gilead Sciences. ************************************************************ Deloitte Recap’s Free Webinar, Tuesday Morning, Feb. 8, 2011 Topic: “Year-End Summary and Analysis of Key Clinical Developments in 2010” Join Deloitte Recap's free, live webinar Date and Time: February 8, 2011,10:00-11:00 AM Pacific / 1:00-2:00 PM Eastern Cost: Free Register at http://www.recap.com/882575E5007F1AA1/w_WebinarReg?OpenForm&U=502ED6EA8187E6CF88257752000BEBC1 Topic Description

Join us on February 8th for a review of key clinical developments from 2010. Using data available in Deloitte Recap's clinical database, DEVELOPMENT optimizer™, we will review key trends from 2010 in the areas of new drug approvals and label expansions, compound and project terminations, and what's in the pipeline. Find out what clinical events made our Top 10 Lists for 2010 and hear our insight s on what might be expected in 2011. We'll highlight the year's most exciting clinical successes, dramatic late-stage failures, and important clinical news about compounds.

Business development Biopharma corporate executives Portfolio management professionals Clinical development and regulatory affairs decision makers

CFOs and financial executives

*********************************************************** Bio2Device Group, Tuesday Evening, Feb. 8, 2011 Topic: “Collaborations between Physicians and Industry - Effect of the 2012 Sunshine Law” Speakers: Moderator: Allan May, Managing Director, Emergent Medical Partners; Panelists: Gary Fanton, MD Stanford Univ.; Peter Fitzgerald, MD Stanford Univ. Date and Time: Tuesday, Feb. 8, 2011, 6:00 pm Location: Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306 Register at www.bio2devicegroup.org week prior to meeting Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins Topic Description In 2012 the Sunshine Act will take effect, requiring yearly reporting of all compensation from manufacturers to physicians over a cumulative value of $100. Many expect that the Sunshine Act will have the biggest impact on medical device companies, as they are much more reliant on physician input during product development than other industry segments. Indeed, as In Vivo recently noted, “… most of the ideas for new device technologies have come, directly or indirectly, from physicians themselves.” * This panel will explore the potential effect of the Sunshine Act on the physician/industry relationship going forward. We will hear from an expert panel of physicians and company executives discussing key questions, such as: • How will this new approach effect the development of better drugs and devices? • How will access to this information effect the practice patterns of health care providers, if at all? • Will physicians be deterred from consulting to industry? • What new practices will medical device companies need to implement in order to maintain their dialogue with medical personnel?

Speaker Bios

Allan May is Managing Director of Emergent Medical Partners, a life science investment firm that focuses on early stage medical device and healthcare companies. Allan has been a founder, board member and/or CEO of a number of early stage companies in medical device and biotechnology including Athenagen, MAST Immunosystems, Intella Interventional Systems, Quanam Medical, ImmuneTech, NuGEN Technologies, AngstroVision, IntegriGen, Imetrx, and Vascular Architects. Previously, Mr. May was Senior Vice President of Diasonics, Inc., a medical imaging company manufacturing and distributing MRI, ultrasound, fluoroscopic and therapeutic devices, and President and COO of Fortune Systems Corporation, a developer of microprocessor based file servers utilizing the Unix operating system. He also has extensive experience in negotiating and consummating M&A, having been involved in over 100 transactions. He co-founded Life Science Angels in 2005 and currently serves as its Chairman.

Dr. Gary Fanton is the Chief of the Section of Sports Medicine at Stanford’s Department of Orthopedic Surgery. He is Board Certified by the American Board of Orthopedic Surgery and is currently the Team Physician in Orthopedics for the San Francisco 49ers. He co-founded the SOAR clinic, where he has been an active partner in private practice since 1983.

Dr. Fanton was a co-founder and board member of Oratec Interventions, a medical device start-up for minimally invasive spine and joint procedures that went public in April, 2000, which was subsequently purchased by Smith-Nephew in 2002. He actively serves on the medical advisory board for several public and private surgical device companies in the orthopedic industry and continues to design and develop unique surgical devices for minimally invasive surgery. He has co-authored several device patents and has several others pending.

Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. Dr. Fitzgerald’s laboratory includes 14 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 95 clinical trials, published over 300 manuscripts/chapters, and lectures worldwide. Peter has been principal/founder of eleven medical device companies and transitioned eight of these to large medical device companies. In 2001, Peter co-founded LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco.

******************************************************************

East Bay Chapter, AWIS, Tuesday Evening, Feb. 8, 2011 Event: Networking Social Date and Time: Tuesday, February 8th, 2011, 630pm – 8pm Location: Pyramid Breweries, 901 Gilman Street, Berkeley, CA 94710 Cost: FREE (Cash Bar) RSVP at: http://events.linkedin.com/ebAWIS-February-Networking-Event/pub/523510 Please join us at Berkeley’s popular brewery, PYRAMID, for an informal gathering of AWIS members and friends!

Directions: www.pyramidbrew.com/alehouses/berkeley Everyone is welcome, including non-scientists and men. If you are not an AWIS member yet, please join us! If you cannot make this month’s social, there will be others! It’s 2nd Tuesday of every other month. Next one will be in April. ********************************************************************* San Francisco AWIS, Wednesday Evening, Feb. 9, 2011 Event: Social Networking Date and Time: Wednesday, February 9th, 2011 -- 6:30 - 8:00pm Location: Bissap Baobab, 2323 Mission Street, San Francisco Cost: Free All professionals in the sciences, students, and friends are welcome! For additional information check http://www.sfawis.com/ **************************************************************** UCSC Ext. Bioscience Product Marketing, Feb. 10 – March 10, March 24, 2011 Dates and Times: Thursday Evenings, Feb. 10-March 10, March 24, 2011 Location: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara Tuition: $825 (Early enrollment - $742.50 through Jan. 27, 2011) Details at www.ucsc-extension.edu/BPM Lead Instructor: Audrey Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.com as life science business development and marketing consultant, has more than 25 years of managerial experience in marketing and business development in the biotech and pharmaceutical industry. She was Executive Vice President and cofounder of Kowa Research Institute and held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad. Guest Lecturers:

Richard Clark, Senior Director, Operations, Ayrx Therapeutics has over 25 years of successful biotech and pharmaceutical sales and marketing experience, including product, managed care, clinical marketing and sales management. He has extensive cross-functional biotech experience in large and small companies with a current focus on managing all aspects of commercial development. Topic – "Product Management 101- Developing/Executing The Tactical Plan"

Chris Mahoney, MPA, is Director, Healthcare Strategy at Cynergy Systems, a software concept, design and development agency, where he is working with healthcare organizations, creating customized software solutions to deliver great user experiences and drive deep engagement. Prior to Cynergy, Chris has held positions at WebMD, IMS Health and Wolters Kluwer Health. Topic - "Patient Adherence: The Impact on Brand Performance."

Charles Versaggi, Ph.D., is President of Versaggi Biocommunications®, a strategic marketing consultancy for biotechnology, pharmaceutical and medical technology companies. With more than 25 years' experience in marketing and communication, Versaggi has directed corporate and marketing initiatives for

nearly 200 companies, ranging from startups to Fortune-100 global leaders. Topic – "Building Value through Strategic Marketing Planning and Communications."

Steven Wong, B.A., is a senior consultant at Plan A, a strategic marketing consulting firm servicing biotechnology and pharmaceutical companies. At Plan A, he has directed numerous consulting engagements, including opportunity assessments, complex population modeling, and therapeutic area. Topic – "Market Research Information Resources."

Additional timely talks will be made by: Naina Shehzeen Ahmad, M.S., is a Senior Consultant, Simon-Kucher &

Partners, in the Life Science division in San Francisco. Her professional focus includes strategic development, value and market access planning, pricing and value positioning strategies, and reimbursement strategies, for pharmaceuticals, biotech, med tech products, and molecular diagnostics. Topic: “Role of Pricing and Reimbursement in Product Management Strategic Planning.”

Deb Donovan, Consultant, eGold Solutions, is an expert in commercial medtech product development and eMarketing, working on products that served the ENT, Orthopedics/Spine, Ob/Gyn and Oncology surgery specialties. She worked at Somnus, Kyphon and Conceptus, Inc. and, most recently, was a Senior Manager at Intuitive Surgical. Topic: “E-Marketing: Activating Patients in a Web 2.0 World.“

Topic Description This product marketing and selling-focused course gives participants an in-depth look at product planning and research, marketing planning, and promotional execution practices in the bioscience industry. Topics include market research methodologies, information sources and applications relevant to product planning; the development of marketing strategy, product positioning and differentiated claims; and the creation of tactical marketing programs and activities to maximize revenue potential. Course activities include the creation of a preliminary marketing plan. The course is well suited for all levels of professionals in bioscience marketing research, product management, product sales, advertising, public relations, business development and licensing, as well as other related functions, such as regulatory, clinical and legal. In this course students as members of a team build a marketing plan for a product of their choice. ************************************************************* Bio2Device Group, Tuesday Morning, Feb. 15, 2011 Topic:”Past Learnings to Future Opportunities in Emerging Markets” Speaker: Ravi Kiron, Adjuvant Date and Time: Tuesday Morning, Feb. 15, 2011, 8:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Park in Street and in NOVA and library parking lots across the street. Speaker Bio Dr. Ravi Kiron has 24 years of experience in the pharmaceutical and healthcare industry and is well versed in all aspects of drug discovery and delivery; pre-clinical and early clinical drug development; bioinformatics and database management; M&A, investment due-diligence, and alliance management. In a consulting practice for the last few years, he has provided business development and strategic advisory, regarding pipeline

challenges and asset sales of discovery and development programs, IP and manufacturing plants, to clients in the pharma and biotech space, and Private Equity and Hedge Fund firms in the US/EU and Asia.

Prior to Adjuvant, Dr. Kiron was the COO at LifeTech Innovations (LTI), a Business Development and Strategic Advisory consulting firm. Dr. Kiron is also a cofounder of C2N Diagnostics, LLC that is in the CNS diagnostics arena. Before LTI, he was at Johnson & Johnson/ALZA Corporation. Prior to that at Pfizer, he was a primary architect of many US/non-US based partnerships, an acquisition/integration team member. Dr. Kiron obtained experience in exploratory drug development as the project champion at Pfizer that led to the IND filing of Tarceva®, now used for treatment of multiple malignancies. Prior to Pfizer, Dr. Kiron was a biochemistry and medicine faculty member at Cornell University Medical Center in New York.

He holds a BSc in Chemistry and an MSc in Microbiology through colleges in Goa from Bombay University, India. He also earned a PhD in Biochemistry from the Indian Institute of Science in Bangalore, India and an MBA from Rensselaer in Hartford, Connecticut.

*************************************************************** San Jose BioCenter, Wednesday Midday, Feb. 16, 2011 Topic: “Life Science Industry & Social Networking” Date and Time: Wednesday | Feb. 16, 2011 | 11:30am Location: San Jose BioCenter, 5941 Optical Court, Second Floor, San Jose, CA 95138 Cost & Registration • Regular Price: $30 • Partners' Network: $20 • BioCenter Members: Free (please RSVP to events@sjbiocenter.com) • On-site Registration: add $10 to the above. Topic Description Social networking has changed how we communicate, build relationships, and influence each other. It is also changing how you do business, attract investors, media, partners, patients & physicians. This workshop will explore what kinds of social media programs and tools are being used by leading life science companies today and how business networking will change as companies fully embrace this new communications paradigm.

Learn how Facebook can engage retail investors. See case studies on how Pharma is using Twitter and how business networking is

happening on LinkedIn. Explore and discuss what the ultimate life science social network should do for

partnering and business development. *************************************************************** BioScience Forum, Wednesday Evening, Feb. 16, 2011 Topic: "Innovate Your Life Sciences Business Model Through Ecosystem Mapping" Speaker: Ed Yu, Director, PRTM Date and Time: Wednesday, Feb. 16, 2011, 6:00-9:00 pm Agenda 6:00 pm - 7 pm networking 7:00 pm - 8 pm dinner

8:00 pm - 9 pm presentation Location: Clarion Hotel, 401 East Millbrae, Millbrae, CA 94030 Event Registration ($3 service fee will apply) General Pre-Registration - $45 General On-Site Registration -$55 Student Pre-Registration -$35 Student On-Site Registration - $45

Parking is $2, which is the discounted rate and can be pre-paid at the registration desk. Otherwise, regular hotel parking fees will apply at the gate. Topic Description Promising technologies, products, and services need to be coupled with a compelling business model to be truly successful and innovative, especially in the highly competitive and rapidly evolving fields of Healthcare and Life Sciences. Ecosystem Mapping, or evaluating one’s business in the co-dependent network of customers, competition, regulators and collaborators within which we operate, allows one to better address difficult questions like “What is our value proposition? To which customers is it addressed? How will the value be delivered? How will our assumptions be affected by changes within our ecosystem?" It is essential to carefully design how products and services grow, evolve, and interact with other components of this dynamic ecosystem. In this session, we will explore Ecosystem Mapping as an innovation tool for evaluating these inter-dependencies, identifying new growth opportunities, defining business models, and ultimately enabling successful commercial launch and competitive advantage in the market. Speaker Bio Ed Yu is a director in the global health care practice at management consulting firm PRTM. He has 30 years of experience in product innovation and development, product strategy, portfolio management, commercialization, and business planning across many industries. He has led growth and innovation transformation projects for medical device and diagnostic clients. Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum 1442A Walnut Street, #308 Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, February 10th If paying with check, do not complete online registration with Cvent **************************************************************** Palo Alto AWIS, Wednesday Evening, Feb. 16, 2011 Topic: “Embracing Your Inner Critic” Speaker: Pat Duran, Business Consultant and Coach Date and Time: Wednesday, February 16th, 2011, 7.00PM-9.00PM

Register at https://www.cvent.com/EVENTS/Register/IdentityConfirmation.aspx?i=6c45e45a-7d2f-494c-9c25-f014a52236f9 Pre-Registration ends Monday, February 14th, at 9 pm Cash or check accepted on the day of the event

Location: PARC, 3333 Coyote Hill Road, Palo Alto, CA 94304 Cost: $5 for Palo Alto AWIS members and students, $10 for non-members RSVP http://www.acteva.com/go/pa-awis Topic Description Do you sometimes feel like there's something holding you back from accomplishing your goals? Do you ever hear an inner voice telling you you're not enough or too much of something? If so, odds are you don't feel very friendly toward it. You may find, however, that this voice has wisdom and can become one of your greatest allies. Learn to use its insights, become more confident, and overcome obstacles to your success. Speaker Bio Pat Duran, a business consultant & coach, her passion is helping women be successful doing work they love. Pat has worked with Fortune 500 companies (Hewlett-Packard, IBM, GM, Alcoa), mid-size companies, and start-ups companies. She co-authored Incredible Business and has been helping both groups and individuals navigate through major change for decades. Pat is a Master Practitioner of Neuro-linguistic Programming, a Dream Coach, True Purpose Coach, Too Young to Retire Coach and Grief Recovery Specialist. You can contact her at : email: pat@patduran.com, phone: 408.972.1200. *************************************************************** Engineering in Medicine and Biology Society (EMBS), Wednesday Evening, Feb. 16, 2011 Title: “The Basics of Intellectual Property” Speaker: James Fox, PhD, Patent Attorney, Arnold & Porter LLP Wednesday, February 16, 2011, 7:30 pm Location: Room M-114, Stanford University Medical School Optional dinner location change: Stanford Hospital Cafeteria, 6:15 pm (no host, no reservations) Details at Santa Clara Valley Chapter http://www.ewh.ieee.org/r6/scv/embs Topic Description This talk will cover topics such as: What is intellectual property (IP)?; How does IP fit in with the business factors that investors consider when placing a value on a company?; What are the timelines for protecting inventions worldwide?; What goes into a patent application? Speaker Bio James Fox is an associate in the intellectual property practice group in the Palo Alto office at Arnold & Porter LLP. He has extensive experience preparing and evaluating patents for biotechnology, medical device, and pharmaceutical clients worldwide. His biotechnology experience includes preparation and prosecution of antibody, growth factor, medical diagnostic and small molecule patent applications. He also has experience in preparation of patentability, freedom-to-operate, and non-infringement opinions, participated in intellectual property due diligence reviews, and has negotiated and prepared technology licenses for medical device companies. Prior to practicing law, Dr. Fox was a product line manager at Axon Instruments, a biomedical instrumentation company (now a division of Molecular Devices, part of MDS); a research scientist at Neurex, a biotech company

developing peptide therapeutics (acquired by Elan Pharmaceuticals); and a post-doctoral fellow at UCSF and UCLA performing research in physiology and ophthalmology. Dr. Fox's research includes stroke research, vision research, and other areas of physiology and biophysics. He is an inventor on eight issued patents. JD, Santa Clara University School of Law, 1999 PhD, University of California, Los Angeles, 1984 BA, University of California, Santa Cruz, 1977 ************************************************************** BayBio Therapeutic Focus, Thursday Afternoon, Feb. 17, 2011 Topic: “Therapeutic Focus: A Mouse Trap Without the Mouse: The New Frontiers in Bio-Safety Models” Moderator: John R. Manthei, Partner, Latham & Watkins Panelists: Ananth Kadambi, Vice President of R&D, Entelos, Inc. David A. Lustig, Ph.D., VP, Business Development, Optivia Biotechnology Inc. Moo Yeal Lee, Lead/Senior Scientist, Solidus Biosciences, Inc. Date and Time: Thursday, February 17, 2011 Registration Opens: 3:30pm Panel Discussion: 4:00pm - 5:30pm Networking Reception: 5:30pm - 6:30pm Location: South San Francisco Conference Center,255 South Airport Blvd., South San Francisco, CA Cost: Pre-registration through February 13 $20 BayBio Members | $40 Non-Members On-site registration on February 17 $40 BayBio Members | $75 Non-Members Topic Description Before the testing of an experimental drug in humans can commence, it has to fulfill certain efficacy and undoubtedly conform to the established safety criteria. Both in vitro and in vivo tests are performed to assess the drug's toxicity and safety margins. Traditionally animal models are used to predict ultimately a product's safety in humans. Increasingly alternatives emerge, such as predictive computer, cellular and tissue models. The development of reliable tools suitable for industrial applications not only promises to do this at a fraction of the cost and time, but be potentially identifying health risks more reliably than even human pivotal trials and without the usually associated liability. A panel of company representatives will examine use of traditional vs. alternative models: pros and cons, reliability and variability, costs and viability, as well as FDA and EMA approval process impact. ******************************************************************** Annual HR Life Sciences Forum Sponsored by BOLD, Thursday Evening, Feb. 17, 2011 Topic: “The State of the Life Science Industry: Trends, Issues and Possibilities for the Future” Guest Speaker: James Sabry, VP of Genentech Partnering and former CEO of Cytokinetics speaking on topic of “Partnering and Trends in Drug Discovery” Date and Time: Thursday, February 17th, 4 – 6:30pm Location: Exelixis in South SF

Registration: www.ls_hrforum_2011.ezregister.com Cost: BOLD members: Free with current membership, $20 at the door Non members: $35 in advance, $45 at the door

For more information visit: http://www.growbold.com/home/2010/12/annual-life-sciences-hr-forum-february-17-2011.html

**************************************************************** Product Realization Group (PRG), Thursday MidDay, Feb. 17, 2011 Topic: “How to Fix the Gaps in Your Medical Device Development” Speakers: Mark Brinkerhoff, President, FusionDesign; Walt Maclay, President, Voler Systems; Rajan Patel, Medical Device Entreprenuer Date and Time: Thursday, February 17, 2011 from 11:30 AM - 1:30 PM (PT) Location: National University, 3031 Tisch Way, San Jose, CA 95128-2530 Cost: $8.50 plus small registration fee of $1.46 Register at http://prg-feb-medical.eventbrite.com/ Topic Description Medical device companies require a deep understanding of the process, and a comprehensive set of capabilities to avoid the increased costs, schedule delays, and FDA regulatory problems resulting from gaps in the development process. The speakers will highlight their experiences in this field from multiple points of view. Mark Brinkerhoff and Walt Maclay will share their product design / prototype development perspectives. To round out the discussion, Rajan Patel, a medical device entrepreneur, will provide his viewpoint of an active growing technology based medical device company. By attending this presentation, you will learn more about: • Identifying gaps in the development process • Setting up an FDA compliant design control process • Product Verification and Validation (V&V) • Avoiding problems with the FDA • Effective Project Management If you are currently engaged in the development of technology based medical products, and are interested in learning from industry experts how you can improve your design practices, and learn more about how to identify and fix the gaps in your process, then this session is for you. To make sure your questions are addressed, please email them in advance when you register or raise them during the session. Attendees: Design Engineers and Management, Operations/Manufacturing Engineers and Management, and all involved in the development of medical technology products from small to large companies. *************************************************************** Bay Area Clinical/Regulatory Roundtable (BACRR), Thursday Afternoon, Feb. 17, 2011 Topic: “FDA Final Rule on IND Safety Reporting” Speaker: Sally Van Doren, PharmD, President and CEO, BioSoteria, Inc. Date and Time: Thursday, Feb. 17, 2011, 3:00 – 4:30 pm Location: Janssen Alzheimer Immunotherapy, 700 Gateway Blvd., South San Francisco, CA 94080, California

Register at http://www.bacrr.org/bacrr/calendar.cfm?eventID=36 Seats are limited. Reserve your seat by sending your RSVP immediately. Thank you. Speaker Bio Dr. Van Doren is President and Chief Executive Officer of BioSoteria, Inc. a drug safety and risk management consulting firm headquartered in Emeryville, CA. She has over 21 years of biotechnology and pharmaceutical industry experience and has been directly involved in management of all aspects of safety surveillance operations, clinical and postmarketing signal detection, safety data analyses, pre- and post-marketing risk assessment, authoring sections for NDA, BLA, and MAA submissions, REMS and EU-RMP development, and product labeling and company core data sheets (CCDS). Dr. Van Doren has advised over 60 companies while serving as a senior consultant at BioSoteria on a broad range of product safety issues. She has also served as an expert legal witness regarding product safety liability issues. Prior to founding BioSoteria, she previously held leadership positions in drug and biologic safety, clinical drug development and medical affairs at Gilead Sciences, Cerus Corporation, Peninsula Pharmaceuticals, Intermune and Syntex Laboratories. Prior to entering the pharmaceutical industry, Dr. Van Doren conducted drug utilization studies at an international tertiary care hospital and research center in Saudi Arabia. She also previously provided poison and medical information at the Maryland Regional Poison Center. She is presently an Adjunct Assistant Professor in the Department of Pharmaceutical Health Sciences Research at University of MD School of Pharmacy and an Instructor in drug safety at University of California Berkeley Extension as part of the Clinical Research and Management Certification Program, is an invited instructor at UCSF School of Pharmacy on drug safety topics, is a Member of the Board of Visitors at the University of MD School of Pharmacy, and is a Member of the Community Advisory Board, UCSF AIDS Health Project. Dr. Van Doren has a Doctor of Pharmacy degree from the University of Maryland School of Pharmacy and completed a residency in clinical pharmacy at University of California San Francisco Medical Center. She has published over 40 articles in the area of drug safety, safety assessment, risk management, and drug utilization as well as co-author on several clinical studies during her career. *************************************************************** Bio2Device Group, Tuesday Morning, Feb. 22, 2011 Topic: “Blending Nature & Science” Speaker: Shirley X. Chen, Ph. D., J.D., Co-Founder, President & CEO, WinVivo Date and Time: Tuesday, 02/22/2011 - 8:30am Event Location: Sunnyvale City Council Chambers, 456 West Olive Avenue, Sunnyvale, CA

Speaker Bio Dr. Chen has a unique combination of expertise and experience in the areas of global botanical product development and market expansion, pharmaceutical and biotechnology intellectual property (IP) protection and brand management, which are built upon her 10+ years of academic research in the areas of cancer biology, virology, molecular biology and biological chemistry. Dr. Chen served as president and CEO of MEBO International, Inc., a US subsidiary of MEBO International Group headquartered in Beijing, China, a pioneering company that invents and commercializes innovative botanical products for regenerative medicine. Prior to joining MEBO, Dr. Chen was a senior IP counsel at Wilson Sonsini Goodrich & Rosati

(WSGR). During her 9 years of tenure at WSGR Dr. Chen provided strategic counseling for technology companies and investment firms in IP portfolio design and management, technology licensing, IP due diligence and risk assessment, which covered diverse areas of pharmaceuticals, biotechnology, medical devices, nutraceuticals and cosmeceuticals. In her 7 years of doctoral and postdoctoral research, Dr. Chen had carried out interdisciplinary studies in interactions of small molecules with biomolecules in the development of innovative anti-cancer drugs and molecular diagnostics; and later as a principle investigator she led research in cancer biology and therapeutics development at SRI International.

***************************************************************** BayBio Nest, Thursday, Feb. 24, 2011 Event: 8th Annual Investor & Entrepreneur Roundtables Date and Time: Thursday, February 24, 2011 5:00 p.m. – 6:30 p.m. Networking Reception 6:30 p.m. – 8:00 p.m. Roundtable 8:00 p.m. – 8:30 p.m. Dessert Break 8:30 p.m. – 9:30 p.m. Roundtable Location: Crowne Plaza Cabana Hotel, 4290 El Camino Real Palo Alto, CA 94306 Parking: Complimentary on-site Cost: Investors: Complimentary, Entrepreneurs: $40.00 by Feb. 20th | On-site: $80.00* Other: $60.00 by Feb. 20th | On-site: $100.00 Details and registration at http://www.baybio.org/events/details/8th-annual-entrepreneur-investor-roundtables/ Event Description The Entrepreneur and Investor Roundtables is a unique event designed to facilitate introductions, dialogue and connections between life science entrepreneurs and investors. This event provides early stage companies with an accessible first step into capital markets while providing investors a first look at intriguing innovations. The Entrepreneur and Investor Roundtables event is well known for its iconic ‘speed-dating’ format. Each year, VC firms and Angel Investors listen to brief pitches from dozens of biotech entrepreneurs.

The speed dating format is designed to let early stage entrepreneurs pitch to as many as 30 major regional VC investors, angels and corporate venture groups in a span of one evening.

Entrepreneurs will be able to review investor profiles and investment areas on a Web site prior to the event. Investors will have access to profiles of emerging companies.*

This is an outstanding opportunity to make contacts with key funders and get on their radar early.

******************************************************************* Stanford School of Neurosurgery and Bio-X, Monday, Feb. 28, 2011 Topic: “Rewiring the Brain: Present Realities, Future Hopes: A day of interactive lectures on Neuromodulation” Date and Time: Monday, Feb. 28, 2011; 7:30am-3:30pm

Location: Clark Center Auditorium, 318 Campus Dr., Stanford, CA 94305 Cost: Free Registration: http://access.stanfordhospital.org/events/ Contact: Barbara Benton, Phone: 650-723-9717, bbenton@stanford.edu Agenda Translating Concept To Clinic In Neuromodulation (The Story Of Anterior Nucleus Stimulation For Epilepsy) Robert Fisher, Md, Phd Closed Loop Control Of Neurostimulation: Where Are We Now And Where Will We Be In 10 Years? Martha J. Morrell, Md The Circuitry Of Mood And Potential Modulatory Sites Hugh Brent Solvason, Md, Phd Abnormal Brain Oscillations: Their Identification And Modulation For Treatment Of Brain Diseases Helen Bronte-Stewart, Md, Mse Fmri "Engrams" - Personalized Profiles Of Pain And Emotion Sean C. Mackey, Md, Phd Deep Brain Stimulation For Cognitive Enhancement Andres Lozano, Md Rethinking Depression And Its Treatment: Insights From Subcallosal Cingulate Dbs Helen S. Mayberg, Md Toward Clinically Useful Neural Prostheses Krishna Shenoy, Phd Optogenetic Targets For The Treatment Of Human Disease Karl Deisseroth, Md, Phd Legal And Ethical Issues In Translational Therapeutics Hank Greely The Neuromodulation Center At Stanford – Bringing Scientific Insights To Clinical Fruition Jaimie M. Henderson, Md ******************************************************* San Jose Biocenter, Monday Afternoon, Feb. 28 2011 Topic: “Maximizing Your Non-Dilutive Funding Potential” Speaker: Ram May-Ron – Managing Partner, Freemind Date and Time: Monday, Feb. 28, 2011 12:00 PM - 12:30 PM Registration, Lunch, and Networking 12:00 PM - 1:00 PM Presentation 1:00 PM - 1:30 PM Q & A 1:30 PM - 5:00 PM One on One Meetings Location: The San Jose BioCenter, 5941 Optical Court, San Jose, CA 95138 Cost & Registration * Regular Price: $30 * Partners' Network: $20 * BioCenter Members: Free (please RSVP to events@sjbiocenter.com) * On-site Registration: add $10 to the above Space is limited for this event, so early pre-registration is recommended to avoid disappointment on the day! Topic Description We are witnessing a continuous movement by the NIH and DOD towards the life science industry, with a greater understanding as to the industry's needs, focus, and difficulties. The scope of funding support given to industry R&D efforts from non-dilutive sources such as NIH and DOD covers the entire R&D cycle from early stage exploratory activities and all the way to late stage clinical research activities (Phase I, II and II). All non-dilutive sources are now expressing greater than ever interest in the R&D efforts of the industry, and more so in the unique set of skills and assets presented by collaborative academia-industry alliances.

This presentation will discuss the latest trends at the NIH and DOD and the new available funding opportunities, in particular: * The challenges in putting together a complex and large scale application * Short term/large scale funding opportunities * Process for applying, requirements and limitations * How to maximize chances for success * Industry & academia collaboration * Government funding as a strategic source of funding Participants in this session will receive an additional 20% off any future work with FreeMind. This offer is exclusive to attendees of the BioCenter Event: Maximizing your Non-Dilutive Funding Potential. Speaker Bio For the past 8 years Ram May-Ron has been a leading figure within FreeMind. Initially leading FreeMind's Professional Services Department and later becoming a partner and part owner of FreeMind and taking upon himself the full responsibilities of both FreeMind's marketing and business development efforts, as well as the overall management of FreeMind's professional services activities. Mr. May-Ron has more than 15 years of experience as a leading strategic analyst, both in the business and political sectors. He has led a strategic consulting firm and has served as a top strategy advisor to several international organizations and elected political officials. Mr. May-Ron serves on the board of directors for several companies and has a wide range of experience in marketing and business development. Mr. May-Ron holds an MEI (Master of Entrepreneurship and Innovation, International Business Management) from Australia’s Swinburne University of Technology. He also holds a Masters degree in International Relations, focusing on strategic decision making processes from the Hebrew University of Jerusalem, winning the International Relations Department’s academic excellence scholarship. ********************************************************************* FountainBlue Life Science Entrepreneurs’ Forum, Monday Evening, Feb. 28, 2011 Topic: Medical Diagnostics: The Advancements and the Opportunities Panelists: Facilitator Katherine Tynan, Tynan Consulting LLC; Panelist Marijke Annis, CardioDX; Panelist Klaus Hambuechen, The Angels Forum; Corporate Panelist to be confirmed; Presenting Entrepreneurs to be confirmed Date & Time: Monday, February 28 from 5:30 - 7:30 p.m. Location: UCSC Extension, 2505 Augustine, Santa Clara Pre-register: $21 members, $32 partners to AudreysNetwork members (respond at http://www.svlifescience.com), $42 general Late and On-Site: $42 members, $52 non-members Members and Prospective Members can register at: http://fountainblue.shuttlepod.org/lifescience Non-Members and Partners can register using the PayPal link at: http://www.svlifescience.com Pre-registration Deadline: February 25 at noon To add questions, answers and resources on this and other FountainBlue topics, visit our crowdsourcing resource at Quora http://www.quora.com/Linda-Holroyd/questions Audience: Life Science entrepreneurs, intrapreneurs and investors, no service providers please

Topic Description Medical diagnostics can range from devices that work with mobile solutions to monitor and communicate key health indicators to tools made available to surgeons to dynamically direct treatment real-time to leveraging genomics as indicators for disease risk. This month, we will cover how diagnostics is quickly advancing and offering more sophisticated, tailored solutions for patients and providers alike. Facilitator Dr. Katherine Tynan, Tynan Consulting LLC Dr. Tynan has over 15 years of experience and is a seasoned biotechnology entrepreneur with a focus on business development, startup entrepreneurship, fundraising and strategic business planning for diagnostic companies. She also has considerable background in financial analysis, operations, product development and commercialization of new technologies, and she works with diagnostic companies guiding them through product development choices, market analysis, funding and a diversity of business development transactions. Previously, Dr. Tynan was at Vitra Bioscience, a venture-backed biotechnology tools company, where she managed a broad range of functional areas including marketing, business development, operations, finance, legal and IP and participated in raising over $15M in capital. She worked at Applied Biosystems in strategic planning (including Celera and Celera Diagnostics), business development, research management and product development roles. Dr. Tynan also directed the Molecular Genetics Department for Oncogenetics and Datagenetics, a start-up esoteric diagnostic services company (acquired by Impath). Board-certified in Clinical Molecular Genetics with post-doctoral studies on Marfan Syndrome at Stanford University and the Human Genome Project at Lawrence Livermore National Laboratory, both in California, she holds a PhD in Human Genetics from the University of Calgary, Canada and a BS (Honors) in Microbiology from University College Galway, Ireland. Panelist Klaus W. Hambuechen, The Angels' Forum Klaus joined The Angels' Forum (TAF) in 2010 after he retired from Siemens AG. He had served Siemens' Healthcare Sector for 36 years and for more than 20 years as CEO in different Medical Imaging Units. In this time Klaus gained world -wide business, device technology and application knowledge in Computerized Tomography (CT), Interventional Cardiology, Interventional Radiology and Neuro-Radiology (AX) and Ultrasound (US). With his experience in enhancing diagnostic imaging performance, Klaus recognizes the unique and evolving needs and opportunities in today's competitive and regulated healthcare market. He is interested to work with companies in life science and clean technology. Klaus has been a mentor for new responsible leaders. He has enjoyed coaching of collaborative partners and entrepreneurs. As a strategic leader Klaus applied process management tools to enhance R&D and business results. His business and technical expertise allowed him to prioritize on - People (1), Processes (2) Product (3) -and to identify problems and execute solutions in this sequence. By applying challenging perspectives on a business model, Klaus can help to define customers' advantages, the products' or services' time-to-market, the risks and opportunities in light of the anticipated ROI. He has been a Board member of companies partnering with Siemens Healthcare and currently serves as a Senior Director and Board Member for Mochida Siemens Medical Systems in Japan. Klaus holds a MSEE (Dipl. Ing.) from RWTH University of Aachen, Germany in Electrical Engineering and Communication Technology. He has been granted several patents in medical imaging applications for CT and MR which are held by Siemens. **********************************************************************

2011 From the Innovator's Workbench, Tuesday Evening, March 1, 2011 Program: The Founders from the Foundry: Mark Deem, Hanson Gifford, Hank Plan and Allan Will Date and Time: March 1, 2011, 5:30 - 6:30 pm, Reception to follow Location: Paul Berg Hall – Li Ka Shing Center for Learning and Knowledge, 291 Campus Drive, Stanford, CA 94305 For registration information: http://biodesign.stanford.edu/bdn/networking/workbench.jsp Cost: General Admission: $45; Stanford Alumni: $35; The event is free for students and faculty, but you must also REGISTER through our School of Medicine registration system. Register at http://www.certain.com/system/profile/form/index.cfm?PKformID=0x10354067234 For further information please contact: Mary Gorman Biodesign Program (650) 736 1161 marygorman@stanford.edu http://biodesign.stanford.edu/ Program Description The Stanford Biodesign Program, Windhover Information, Wilson Sonsini Goodrich & Rosati and PricewaterhouseCoopers present a unique opportunity to hear the first panel of innovators in the 2011 “From the Innovators Workbench” Series. The Founders from the Foundry will be interviewed by David Cassak, Managing Partner, Windhover Information. We will use this Innovator's Workbench to talk with the leadership from the Foundry - a departure from our usual Workbench events, we'll have the founders and primary leaders of the Incubator - all of whom will participate in a discussion of how Incubators work, what results they've had, and to what they attribute their successes. Speaker Bios For more information about Mark Deem, Hanson Gifford, Hank Plain, and Allan Will, please follow the following link: http://biodesign.stanford.edu/bdn/networking/workbench.jsp#parking ********************************************************************** Bio2Device Group, Tuesday Morning, March 1, 2011 Topic: “Patients, Platforms, and Politics: HIV Viral Load Testing in Sub-Saharan Africa” Speaker: Sam Rose, Ph.D., Principal at Rose Consulting Event Location: Sunnyvale City Council Chambers, 456 West Olive Avenue, Sunnyvale, CA Cost: Free Topic Description This seminar will be a true story describing the education of a technical expert who became involved with a large population of people in extreme medical need (Patients),

who originally believes that technology is the solution (Platforms), and learns that money, logistics, and invention is not nearly enough (Politics). Speaker Bio Dr. Sam Rose is currently Principal at Rose Consulting. He has 24 years of industry experience in molecular diagnostics ranging from bench scientist to Director of Advanced Diagnostics Research at Dade Behring, and most recently as Director of Scientific Affairs at Roche Molecular Systems. He holds 20 US Patents in nucleic acid amplification and detection technologies which have been licensed to both research and diagnostic companies. Sam received his B.A. in Biology at UC San Diego, his Ph.D. in Biochemistry at the University of Illinois/Urbana with Prof. Olke Uhlenbeck, and was a postdoctoral fellow with Prof. Eric Davidson at the California Institute of Technology. While at Roche, Sam’s responsibilities included managing non-registrational studies, external technical relationships, and scientific marketing information for the Virology and Women’s Health Global Marketing teams. Included in the Virology effort were initiatives supporting the HIV viral load “AmpliCare” program for least-developed countries, focusing on Sub-Saharan Africa. ******************************************************************** RAPS, Friday Evening, March 4, 2011 Topic: “Evolving Risk-Based Regulatory Requirements” Date & Time: Friday, 4 March 2011, 7:45 am–4:30 pm Location: Crowne Plaza Mid-Peninsula, 1221 Chess Drive, Foster City, CA Speakers: Geetha Rao, PhD, vice president, risk management and strategy, Triple Ring Technologies, Inc. Leo Eisner, PE, principal consultant, Eisner Safety Consultants Ibim Tariah, technical director, BSI Healthcare Craig J. Coombs, RAC, president, Coombs Medical Device Consulting, Inc. Juergen Stettin, president and CEO, PROSYSTEM AG Topic Description Join your quality and regulatory colleagues from the ASQ Northern California Biomedical Discussion Group and the RAPS San Francisco Bay Area Chapter for a lively and informative one-day workshop addressing evolving risk-based regulatory requirements in three specific key quality and regulatory areas:

IEC 60601-1 3rd edition general, collateral, and particular standards including essential performance, risk management integration, and the impact of changes on industry

Usability and Human Factors verification, validation, and regulatory requirements Clinical evaluation and investigation regulatory requirements

Quality, regulatory and other industry professionals currently working in these areas will leave the program with an expanded and practical understanding of the challenges and opportunities that lie ahead.

Registration for this event will be available by Friday, 28 January! Mark your calendar and be on the lookout for an email with specific registration instructions.

*********************************************************** Palo Alto AWIS, Saturday, March 5, 2011

Event: Winter Workshop: Manage and Polish Your Brand Date and Time: Saturday, March 5th, 2011, 9am-4pm; lunch provided Location: Amgen, 1120 Veterans Blvd. South San Francisco Cost: $40 for members and $55 for non-members RSVP required! Info posted on www.pa-awis.org soon. Registration open after Feb. 5th. Interactive full day seminar with 2 Career Coaches and 1 Image Professional ********************************************************************************************************* The Northern California Chapters of the Association for Women in Science, Saturday, March 5, 2011 Topic: NCC-AWIS Winter Workshop 2011:Manage & Polish Your Brand! Learn how you project yourself and how you’re perceived by others..... Speakers: Christine Young, Chris Fogarty, top career coaches and Julie Kaufman, image professional, will help you leverage your brand. Through working in exercises you’ll learn simple and succinct techniques to help you more effectively promote yourself in the workplace and manage your own career development. If you are currently in a job search, all of these same techniques apply. Date and Tim: Saturday, March 5th, 2011, 9:00am to 4:00pm Location: Amgen, Inc. 1120 Veterans Blvd, South San Francisco Cost: $40 members, $55 non-members, Register via ACTEVA by Monday, March 3rd midnight! Workshop includes continental breakfast and lunch Parking is free and easy All professionals in the sciences, students, and friends are welcome! For additional information check http://www.sfawis.com/ ******************************************************************************************************* Bio2Device Group, Tuesday Evening, March 8, 2011 Topic: “The Asthmatx story – Development of a first of a kind device-based treatment for asthma” Speaker: Glen French, President, CEO and Co-Founder, Asthmatx, a Boston Scientific Company Date and Time: Tuesday Evening, March 8, 2011 Location: Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306 Register at www.bio2devicegroup.org week prior to meeting Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins Topic Description Asthmatx markets the Alair(R) Bronchial Thermoplasty System, which received U.S. Food and Drug Administration (FDA) approval in April of this year. Bronchial thermoplasty is a less-invasive procedure routinely performed under conscious sedation with patients typically returning home the same day. The Alair System delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. The procedure is designed to decrease the ability of the airways to constrict, thereby reducing the frequency and severity of asthma attacks.

Bronchial Thermoplasty System was awarded the 2010 Popular Science "Best of What's New" Award in the Health category. Effective October 27, 2010 Asthmatx became a wholly-owned subsidiary of Boston Scientific Corp. ************************************************************************************************************ San Jose BioCenter, Thursday Afternoon, March 10, 2011 Topic: “Innovation: How BIG BioPharma is Getting it Done” Speakers: Christopher Haskell, PhD, Head, US Science Hub, Bayer HealthCare Pharmaceuticals Sylvaine Cases, Ph.D. Sanofi-Aventis US, External Innovation Yael Weiss, PhD, Director, Licensing & External Research, Merck Research Laboratories Thomas F. Zioncheck, Ph.D, Senior Director, Business Development, Genentech Lead Facilitator: Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP Date and Time: Thurs. March 10, 2011 | 3:00pm - 6:30pm Location: Orrick, Herrington & Sutcliffe LLP, 1000 Marsh Road Building 1100, Menlo Park, CA 94025-1015 Click here for Venue Directions Cost & Registration: • Regular Price: $50 • Partners Network: $40 • Meet with Alumni: $30 • BioCenter Members: FREE (please RSVP to events@sjbiocenter.com) • On-site Registration: add $10 to the above. Topic Description Everyone is talking about innovation. The innovation gap, the importance of innovation, can big companies be innovative, is Silicon Valley still the home of innovation? This panel discussion will feature representatives from BIG BioPharma who will share their efforts to stay on top of the innovation game and how you can participate. Featured initiatives will include grants, venture arms, incubators, funding early stage research, interfacing with VCs and much more. Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception. **************************************************************** Bio2Device Group, Tuesday Morning, March 15, 2011 Topic: Managing Change in a Technology Driven World Speaker: Benny Kirsh, Founder and Principal, TCM Consulting-Technology Change Management Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Park in Street and in NOVA and library parking lots across the street. Topic Description Companies considering the implementation of new systems or upgrading existing ones readiness for a major change in the business, setting realistic expectations or establishing and communicating project values are just a few of the challenges facing managers when required to investment in the company’s future.

Effective Change Management Strategy and execution will mitigate the risk inherited in New Technology implementations and create the sustainable change in the business required to compete in today’s dynamic market. The presentation will discuss the following: - Understanding the difficulty to change - The emotional phases of a Technology driven change - What do the experts say about performing successful changes in organizations. - A framework for Technology Change Management - What are the advantages of a good Change Management Strategy? Take aways: A good change management strategy will: - Minimize the impact on business performance during a technology implementation - Achieve excellent execution results - Create buy-in, engagement and motivation - Create a company culture of collaboration - Sustain effective work standards Speaker Bio Benny has held several top IT Management positions in Life Science and High Tech companies and up to recently as an Executive CIO for The Cooper Companies. He joined the Cooper Companies to lead an ERP implementation and drive a cultural change necessary for a global roll-out. He also led a highly professional IT team in implementing several systems such as financials, distribution, supply chain and others. He instituted a Change Management strategy to create a working relationship based on transparency and accountability. Prior to The Cooper Companies, Benny was the first CIO at Kyphon, while the company was experiencing significant growth. His most important objective was to lay the technology foundation for growth while sustaining the flexibility required for Kyphon to operate in a competitive market. He was responsible for implementing critical systems such as ERP, Quality Assurance, Workflow, Clinical Trial Systems and others. Benny relocated to the US from Israel with an International Enterprise, Terayon Communication Systems, bringing with him a wealth of global experience. Working with a High-Tech company during the dot-com era required flexibility, creativity and innovation on a daily basis. Driving change while implementing new technologies and addressing People-Process-Systems; Benny has found the people segment to be the most challenging aspect of a technology implementation. Benny has always been a strong advocate at investing the appropriate effort in preparing the organization for change. Topics such as Executive commitment, buy-in from the business users and communicating the real value are key components for a successful implementation. ************************************************************ San Jose Biocenter, Wednesday Mid-Day, March 16, 2011 Topic: “Human Biospecimens in the Era of Personalized Medicine” Olga Potapova, Ph.D., Founder, CEO and Scientific Director, Cureline, Inc. Date and Time: Wednesday, March 16, 2011 Agenda

11:30 AM - 12:00 PM Registration, Lunch, & Networking

12:00 PM - 1:00 PM Presentation & Q&A Location: San Jose Biocenter, 5941 Optical Court, San Jose, CA 95138

Cost & Registration: Regular Price: $30; Partners' Network: $20; BioCenter Members: Free (please RSVP to events@sjbiocenter.com); On-site Registration: add $10 to the above Space is limited for this event, so early pre-registration is recommended to avoid disappointment on the day! Topic Description Modern biomedical research requires continuous supply of legally and ethically acquired high quality human biospecimens and associated data. Preservation of pre-analytical biospecimen variables, significantly confounding research of the disease biomarkers and development of modern diagnostics, will be discussed. Other topics include: collection of biospecimens using standard protocols versus custom protocols; effective use of currently available biorepositories for future studies on the indicated subject; relevant regulatory and legal issues, including international disparities in regulations on use of human materials for biomedical research.

Human biospecimens: the foundation of translational medical research Important pre-analytical aspects of human biospecimen procurement:

o tissue collection specifications o processing materials and methods o storage and shipping procedures o analyte preparation techniques

Standard operating procedures: o collection and handling of human biospecimens o legal and ethical considerations o clinical data collection and management

Project-based collection protocols and custom assay development Effective utilization of human biospecimens in modern biomedical research,

including development of new drugs, novel biomarkers and personalized molecular diagnostics

Speaker Bio Olga Potapova is an expert in biotechnology and life sciences business development. Since 2003, Dr. Potapova leads Cureline, the international biomedical project management group of companies working in the areas of human tissue acquisition (www.cureline.com), clinical research consulting (www.CCCPtrials.com), and diagnostics and laboratory services (www.CurelineBioPathology.com). At Cureline, she is responsible for strategic development, international alliance management, new products and services development and expansion into new markets. Previously she worked in the fields of cancer research human molecular genetics and genomics, oncology drug R&D and translational medicine (NIH and Pfizer/SUGEN). Olga has received multiple AACR/AFLAC awards, NIH and NATO fellowships, and has published multiple scientific papers in peer-reviewed journals. Dr. Potapova holds international and US patents, and has advanced degrees in Physics (M.Sc.) and in Molecular Genetics/Biochemistry (Ph.D.). ********************************************************** Bio2Device Group, Tuesday Morning, March 22, 2011 Topic: “TBA” Speaker: To be confirmed. Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free

Park in Street and in NOVA and library parking lots across the street. ********************************************************** Palo Alto AWIS, Wednesday Evening, March 23, 2011 Topic: “Making Chemical Testing Relevant to Breast Cancer: The California Breast Cancer and Chemicals Policy Project” Speaker: Megan Schwarzman, MD, MPH. Research Scientist UC Berkeley School of Public Health Date and Time: Wednesday March 23rd, 2011, 7.00PM-9.00PM 7-7:30 Dinner and Networking, 7:30-9pm Program Location: PARC Auditorium, 3333 Coyote Hill Road, Palo Alto, CA-94034 Cost: $5 for Palo Alto AWIS members and students, $10 for non-members See info at www.pa-awis.org/ closer to event. ******************************************************************** Bio2Device Group, Tuesday Morning, March 29, 2011 Topic: “The Seven Habits of Highly Effective People in R&D” Speaker: Daniel Grupp, Ph.D., Consultant, Procept Corp. Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Park in Street and in NOVA and library parking lots across the street. Speaker Bio Dan has more than 25 years of experience in R&D. His career has covered topics from power electronics, to nanotechnology, to superconductivity, to medical devices. Recently, he was Vice President of Research and Development at Procept Corporation. There, he led a team to build a complex multi-system robotic surgical tool for minimally invasive transurethral treatment of BPH. The team moved the project from bench-top proof-of-concept to full-scale prototype in under six months. The prototype was used in successful animal trials. Prior to Procept, Dan was a Visiting Scholar at Stanford, where he started a company based on his invention of a transistor for the future of digital computing. “When it says Intel Inside,” he says, “we are going to be what’s inside Intel.” Dan sold his company to Acorn Technologies, where he served as Director of Device Development. He negotiated a deal with SEMATECH where the technology is now under codevelopment. Dan has a PhD in nanotechnology physics from the University of Pennsylvania, and a BA in physics from Cornell. He also had a solo show of his sculptures in 2009 at the de Young Museum in San Francisco. The presentation will focus on principles and habits that make one effective in R&D career. Research and development is an adventure into the unknown. As engineers, what is not unknown is that we need to produce results by all-to-well-known deadlines. Yet often projects with promising technologies fail to achieve their goals. There can be many factors from team dynamics to limited funding as the root cause. It may also be the methodology of doing the R&D itself that is the gating factor. In this seminar, I will identify seven key principles to R&D that minimize risk and increase productivity. They are all simple, and likely familiar to experienced engineers, but without being clearly defined, they may not always be kept in mind when making decisions. For example, we all know that walking a tightrope is a high-risk proposition. Yet how often have we walked tightropes in our engineering, requiring everything to be tuned just perfectly for

it to work? Of course, we can all tell success stories, but these are heroic events that are rare, and don’t lead to a productive career—especially for tightrope walkers. People who are successful over the long term know, “Never walk a tightrope”. Applying this principle and six others regularly and consciously can yield dramatic improvements in getting things done in R&D. ********************************************************************** Bay Area Biomedical Devices Conference, Wednesday, March 30, 2011 Date and Time: 03/30/2011 - 8:00am Location: San Jose State University

Bay Area Biomedical Devices Conference, to be held on March 30, 2011.

The Biomedical Engineering Society at San Jose State University is pleased to announce the convening of the 2011 Bay Area Biomedical Device Conference. The purposes of this conference include: (a) Provide a forum for exposure to emerging technologies (b) Hear from entrepreneurs on how to take your ideas to market, and (c)Provide a venue for Bay Area medical device professionals to network. We invite you to join us in this exciting event.

Registration $195 Early Registration (before 5 p.m. March 17) $245 Late Registration $275 Walk-in Registration $50 SJSU Students $75 Non-SJSU Students Welcome! Who should attend?

Sponsors SM

Contacts: Dr. Guna Selvaduray Emily Wong Advisory Committee: Mike Reo, Marc Jensen Sepehr Fariabi, Herb Bellucio Guna Selvaduray, Felix Vega Wednesday March 30

The Speakers Lisa Ferrara, Ph.D., OrthoKinetic Technolgies Topic: Orthopedic Fixation - Novel Biomaterials, Mechanical Testing, and Regulatory Process

Kim Butts Pauly, Ph.D., Stanford University Topic: Recent developments in imaging technologies

Satya Prakash, Ph.D., McGill University Topic: Novel artificial cell probiotics as medical food and pharmaceuticals

Garth James, Ph.D., University of Montana Topic: Biofilm Infections on Medical Devices

Byron Lambert, Ph.D., Abbott Vascular Topic: Sterilization of Medical Devices and its relationship to infection

Roy Bloebaum, Ph.D., University of Utah Topic: Osseointegrated Implants for Amputees: Hopes and Concerns

Debbie Brown, Asthmatx Topic: Medical Devices: The Changing Landscape with FDA

Virginia Giddings, Ph.D., Abbott Vascular Topic: Bioresorbable Biomaterials

Sanjay Shrivastava, Ph.D., ev3 Topic: Engineering Solutions for Treating Cerebral Aneurysms & Ischemic Stroke

Neha Choksi, Leveraging MEMS for Biosensing M. Meyyappan, Ph.D., NASA Topic: Nanotechnology in Biomedical Applications

Sepehr Fariabi, Ph.D. Topic: Shape Memory Alloy Applications in Biomedical Devices

Mark Gonzalgo, M.D., Stanford University Topic: Robotic Surgery

**************************************************************** San Jose Biocenter, Thursday Midday, April 6, 2011 Topic: “All About Science - The Road to Biologic IND” Speakers: Bob Burford, Vice President of Regulatory Affairs, Laureate Pharma and Mike Ultee, Chief Scientific Officer, Laureate Pharma Date and Time: Thursday, April 6, 2011 Agenda 11:30 AM - 12:00 PM Registration, Lunch, and Networking

12:00 PM - 2:00 PM Presentation & Q&A 2:00 PM – 3:00 PM Product Show Location: San Jose Biocenter, 5941 Optical Court, San Jose, CA 95138 Cost & Registration -Regular Price: $30 -Partners' Network: $20 -BioCenter Members: Free (please RSVP to events@sjbiocenter.com) -On-site Registration: add $10 to the above Space is limited for this event, so early pre-registration is recommended to avoid

disappointment on the day! Topic Description Whether your goal is to develop your pipeline through commercial launch, or partner as early as possible, submitting an IND is a critical early milestone. Even with big pharma and VC firms competing for the most promising compounds, the bar is still quite high and startups are expected to demonstrate a solid plan for achieving IND acceptance to be taken seriously. Join us for a series of presentations followed by an interactive panel discussion exploring the basic requirements and considerations you must be aware of when planning for a successful IND submission. Presentations will highlight the following:

Key components of the Chemistry/Manufacturing/Controls Expression, Purification, Analytics, Formulation, Fill/Finish Preclinical study design, species selection, material requirements, timelines and

cost considerations Regulatory requirements, strategies to minimize costs and timelines while

balancing risk Tips for presenting an attractive package for acquisition

Speaker Bios Michiel E. Ultee, Ph.D. , has more than 25 years of experience in the biopharmaceutical industry and has worked with antibodies since 1975. He serves as Laureate Pharma's scientific head and has been part of their biopharmaceutical operations team since 1987. His prior positions include Vice President of Process Sciences and Director of Manufacturing & Technical Operations. Dr. Ultee began his career in Research and Development, where he was part of the team that developed two licensed biopharmaceuticals. He holds four U.S. patents and has published numerous scientific articles. Prior experience includes postdoctoral research in immunology at NYU Medical School. He is a frequent speaker at biopharmaceutical conferences, and a member of the editorial advisory boards of Bioprocess International and Biopharm International. Dr. Ultee earned his graduate and undergraduate biochemistry degrees from Northwestern University and Dartmouth College. Dr. Robert G. Burford joined Laureate Pharma in November 2010 with an impressive career in the pharmaceutical industry that has spanned the past 41 years. Dr. Burford holds a Ph.D. in pharmacology/toxicology from the University of Western Ontario, Canada, and has held various positions with innovator and emerging drug companies, as well as contract research firms. These positions included preclinical pharmacology and toxicology at Bio-Research Laboratories in Montreal, and 17 years at Searle Pharmaceuticals, where he held various positions including Director of Clinical Research, Medical Director of Life Sciences Division, and Director of Scientific Affairs. Thereafter, he was the Director of Clinical Research at Biovail Laboratories, V.P. of Product Development at Axonyx Inc, and V.P. of Preclinical and Regulatory Affairs at Sequoia Pharmaceuticals. For the past 16 years he has been President of the American Clinical Research Consultants Inc. where, as an industry consultant, he has offered expert advice and counsel in preclinical toxicology and early phase clinical development of new drug products and medical devices. He has represented both domestic and foreign clients before the FDA and HPB, being thoroughly familiar with the regulatory requirements of medical product approval in the U.S. and Canada. He is a past president of the Society of Toxicology, Canada, Secretary General of the International Union of Toxicology and a member of the American Society for Clinical Pharmacology and Therapeutics, among others.

***************************************************************** Deloitte Recap Allicense Meeting, Tuesday and Wednesday, May 3 & 4, 2011 Topic: “A New Deal for Biotech: Bringing Innovative Financing and Creative Partnering to the Table” Date and Time: Tuesday and Wednesday, May 3-4, 2011 Location: Westin St. Francis Hotel, Union Square, San Francisco, CA. Register at http://www.recap.com/8825776F006CBDF1/register11?OpenForm by March 31st and save 25% off the regular rate of $1,950. Cost for regular and special discounts:

Regular Registration $1950

Special Registration Discounts

Early Bird $1462.50 (25% discount until March 31, 2011)

Recap IQ Subscribers $1365 (30% discount)

Team Registration - Register two or more employees $1365 (30% discount)

Academic and government participants $975 (50% discount)

Registration fee includes 2 days of conference sessions, continental breakfasts and seated luncheons on both days, and attendance to the Breakthrough Alliance Awards Dinner on May 3, 2011.

Topic Description Allicense is a must-attend event for hundreds of Biotech and Pharmaceutical business development and finance executives each year. Hosted by Deloitte Recap, Allicense provides an opportunity to hear the industry’s leaders discuss the latest trends and leading practices affecting our industry. For general Allicense questions email allicense@deloitte.com.

Interested in presentation or sponsorship opportunities at Allicense? We’d like to hear from you! Please email allicense@deloitte.com.